SanBio Co (TSE:4592) LT-Debt-to-Total-Asset : 0.08 (As of Jan. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. SanBio Co's long-term debt to total assests ratio for the quarter that ended in Jan. 2024 was 0.08.

SanBio Co's long-term debt to total assets ratio declined from Jan. 2023 (0.09) to Jan. 2024 (0.08). It may suggest that SanBio Co is progressively becoming less dependent on debt to grow their business.

SanBio Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for SanBio Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co LT-Debt-to-Total-Asset Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.19

0.37

0.09

0.08

SanBio Co Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.10	0.11	0.11	0.08

SanBio Co LT-Debt-to-Total-Asset Calculation

SanBio Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (A: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jan. 2024 )	/	Total Assets (A: Jan. 2024 )
	=	397	/	5047.291
	=

SanBio Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (Q: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )	/	Total Assets (Q: Jan. 2024 )
	=	397	/	5047.291
	=

SanBio Co (TSE:4592) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

SanBio Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of SanBio Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SanBio Co (TSE:4592) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SNBIF:USA

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines